Skip to main content

Table 1 Mean and standard deviation of demographic characteristics, Viral loads and CD4 + T cell counts at baseline and upon virologic failure according to the HIV resistance profile

From: Dolutegravir-associated resistance mutations after first-line treatment failure in Brazil

 

N

Age (years)a

Males n(%)

Females n(%)

Viral Load at virologic failurea

CD4 at virologic failurea

Baseline Viral Loada

Baseline CD4a

Wild Type HIV

65

35.7(10.27)

42(73.68)

15(26.32)

4.91(5.263)

438(332.5)

5.66(6.112)

391(359)

TL + D RAMS

2

34.0(4.243)

2(100.00)

0(0.00)

5.35(5.413)

53.5(30.41)

6.12(6.112)

45.5(55.86)

TL RAMS

6

37.2(15.79)

3(50.00)

3(50.00)

5.44(5.662)

175(172.6)

5.87(6.029)

161(170.8)

Major INRAMS

7

37.9(14.35)

5(71.43)

2(28.57)

5.01(5.145)

238(218.4)

5.73(5.935)

184(211.2)

Minor INRAMS

18

33.6(10.58)

12(75.00)

4(25.00

5.17(5.411)

281(237.9)

5.77(5.84)

179(178.85)

NRTI RAMS

15

35.1(11.43)

10(71.43)

4(28.57)

5.50(5.853)

221(188.7)

5.90(6.015)

207(193.8)

NNRTI RAMS

16

35.5(12.29)

9(69.23)

4(30.77)

5.17(5.595)

356(200.6)

5.35(5.686)

304(149.8)

PI RAMS

6

38.8(10.43)

4(80.00)

1(20.00)

4.93(5.077)

216(176.8)

5.28(5.286)

212(158.2)

Total

113b

36.1(10.77)

73(73.00)

27(27.00)

5.13(5.55)

365.9(294.1)

5.67(6.034)

323.2(305.6)

  1. The total n of 113 is less than the sum of the n’s in the categories as there were many cases that had multiple categories of RAMs
  2. TL Tenofovir/lamivudine, D Dolutegravir, RAM Resistance-associated mutations, INRAM Integrase resistance-associated mutations, NRTI Nucleoside reverse transcriptase inhibitor, NNRTI Non-nucleoside reverse transcriptase inhibitor, PI Protease inhibitors
  3. aMean(std. dev.)
  4. bone sample failed in the RT and protease PCR amplification